Australian life-sciences firm Invion is leading the global clinical development of a novel PhotoDynamic Therapy (PDT) for cancer. Invion’s novel photosensitiser (the agent used in PDT) is called IVX-PDT and is based on the PhotosoftTM Technology.
Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of the PhotosoftTM technology by licensor RMW Cho Group, which has funded and successfully commercialised a number of unique, advanced technologies.
Invion has an agreement with RMW Cho Group to conduct the clinical development of the PhotosoftTM technology globally. RMW Cho Group provides non-dilutive funding for the research into and clinical trials of the PhotosoftTM Technology via a R&D services agreement with Invion. The provision of non-dilutive funding is part of a global development strategy for the PhotosoftTM Technology.
Invion is collaborating with leading global medical research institutes – the Hudson Institute of Medical Research and the Peter MacCallum Cancer Centre – to progress the PhotosoftTM Technology research program.
Invion has been listed on the Australian Securities Exchange since 25 February 2011 under the ticker “IVX”